VRDN-003-303: Thyroid Eye Disease

A clinical trial studying a potential treatment that is given by subcutaneous injection for people affected by thyroid eye disease (TED).

The VRDN-003-303 clinical trial is studying the investigational study drug called VRDN-003 as a potential treatment for people affected by TED. In VRDN-003-303, researchers are looking to better understand the benefits and safety of VRDN-003 when given through a subcutaneous injection either every 4 weeks or every 8 weeks.